The number of people with susceptibility test result for rifampicin in Norway
Norway: The number of people with susceptibility test result for rifampicin was 98.57 in 2021. ▬ Flat
Latest (2021)
98.57
Change on year
down 0.2%
World rank
36th
of 146 countries
All-time high
100
in 2017
All-time low
89.13
in 2019
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Norway, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for the number of people with susceptibility test result for rifampicin in Norway is 98.57, measured in 2021.
Compared with earlier readings it is down 0.2% on the previous year and down 1.4% over five years.
Norway ranks 36th of 146 countries on this measure, in the top quarter.
The number of people with susceptibility test result for rifampicin in Norway, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 100 | — |
| 2018 | 96.15 | -3.8% |
| 2019 | 89.13 | -7.3% |
| 2020 | 98.78 | +10.8% |
| 2021 | 98.57 | -0.2% |
Norway compared with similar countries
- Norway's 98.57 is above the median for high income countries, which is 92.6, 1.1× the median. (56 countries reporting)
- Norway's 98.57 is above the median for Europe & Central Asia, which is 93.52, 1.1× the median. (43 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 95.09 | 89.13 | 100 | 3 |
| 2020s | 98.68 | 98.57 | 98.78 | 2 |
Countries ranked near Norway
More health data for Norway
- Un projection of annual infant deaths, annual growth rate -7.69 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.337 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,212 deaths per 1,000 people (2090)
- Number of infants who die before age 1 12 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate -0.217 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0238 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.0617 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Norway?
- The number of people with susceptibility test result for rifampicin in Norway was 98.57 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Norway?
- The highest recorded value was 100 in 2017.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Norway?
- The lowest recorded value was 89.13 in 2019.
- How does Norway rank for the number of people with susceptibility test result for rifampicin?
- Norway ranks 36th out of 146 countries with data for 2021.
- Where does this Norway data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).